81 results
Page 2 of 5
8-K
1zw0l0 sj
12 Nov 21
Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS
6:30am
8-K
EX-99.1
0sirrjbmillomi
12 Nov 21
Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS
6:30am
8-K
EX-99.1
0tud82
4 Nov 21
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:40am
8-K
EX-99.1
x9uw6f1k o7qgzy4z
13 Sep 21
Other Events
7:08am
8-K
gs0hjg4b0s0
13 Sep 21
Other Events
7:08am
8-K
EX-99.1
6m5dy66bs zab1dcj
9 Aug 21
Adaptimmune Reports Second Quarter Financial Results and Business Update
4:08pm
8-K
7er 383pu
19 May 21
Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial
5:08pm
8-K
EX-99.1
e1nq49ij1h14hj
19 May 21
Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial
5:08pm
8-K
EX-99.1
7rc1nq35x3soqok q3
6 May 21
Adaptimmune Reports First Quarter Financial Results and Business Update
7:38am
8-K
EX-99.1
7o6k0hltt0f4hrguatlp
25 Feb 21
Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update
7:37am
8-K
EX-99.1
zwno vj2gn
20 Nov 20
Regulation FD Disclosure
7:36am
8-K
2q35y9ohr0k jsyq8
19 Nov 20
Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS
9:09am
8-K
EX-99.1
1hnvrni3 6zx73mcq
19 Nov 20
Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS
9:09am
8-K
EX-99.1
d972qwr849 z8pie
9 Nov 20
Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC
5:11pm